A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ shares tumbling, ...
A post hoc analysis evaluates zanubrutinib vs acalabrutinib-venetoclax in treatment naive chronic lymphocytic leukemia using indirect comparisons of data from two phase 3 trials.
Tovecimig (CTX-009) in combination with paclitaxel significantly improved progression-free survival (PFS), but not overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results